EXAS

NEUTRALM&A

Exact Sciences Corporation

2026-02-27

Price

$103.38

+0.13%

Score8.6Priority

Signals5/8 DNA4/13 Act · 0/4 Risk

SentimentNEUTRALScore: 9

Volume1.2xvs 20d avg

Analysis

EXAS is currently trading as a high-probability merger arbitrage play following its shareholder-approved acquisition by Abbott Laboratories (ABT) for $105.00 per share in cash. The 'Steady Climb' and 'Quiet Storm' signals reflect the gradual narrowing of the deal spread (currently ~$1.62 or 1.6%) as Abbott's recent 8-part bond sale (Feb 23) removes financing risk. While the 'Risk Off' macro regime keeps the spread slightly wider than typical for a closed deal, the price action is driven entirely by the march toward the deal closing rather than organic fundamentals.

Fired Signals

ALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSPERFECT STACKQUIET ACCUMULATIONSMA BOUNCEINSIDE OUTSPRING LOADED

Key Takeaways

**Deal Status:** Shareholders approved the merger on Feb 20, 2026; Abbott's bond issuance this week confirms funding is secured.
**The Arbitrage:** Trading at $103.38 vs. $105.00 cash offer offers a ~1.6% absolute return (safe yield) in a volatile market.
**Risk Profile:** Downside is limited to a highly unlikely regulatory (FTC) block; upside is capped at $105.

← Back to 2026-02-27 View Full EXAS History →Yahoo Finance &nearr;